<DOC>
	<DOC>NCT00823355</DOC>
	<brief_summary>Primary objectives are to evaluate the safety profile and tolerability of oral BCX1777 in each cohort of patients with recurrent or refractory T/NK-cell malignancies and to evaluate pharmacokinetics (PK) of oral BCX1777.</brief_summary>
	<brief_title>Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically documented with histopathological diagnosis from biopsy, T/NKcell malignancies (WHO classification). Precursor Tcell lymphoblastic leukemia/lymphoma (TALL/TLBL) should be excluded in this study A patient with recurrent, relapse or refractory T/NKcell malignancies who has received at lease one chemotherapeutic regimen Age 20 or greater Eastern Cooperative Oncology Group(ECOG) performance status:0,1. Able to be hospitalized at least for 15 days from the first dose In the case of subject with tumor cell rate of ≤25% in bone marrow, a patient who satisfies both of the following criteria. Neutrophil count: ≥1,200/mm3 Platelet count: ≥75,000/mm3 In the case of CTCL, the tumor cell rate is handled as ≤25%. Adequate Liver function: AST, ALT ≤ 5.0 x upper limit of normal (ULN) Adequate Renal function: Creatinine Clearance (using cockcroftGault formula) ≥ 50mL/min Life expectancy of at least 3 months A patient who has given a written informed consent prior to the start of procedures proper to this study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>